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Conversion of one terminally differentiated cell type into another
(or transdifferentiation) usually requires the forced expression of
key transcription factors. We examined the plasticity of human
insulin-producing b-cells in a model of islet cell aggregate forma-
tion. Here, we show that primary human b-cells can undergo
a conversion into glucagon-producing a-cells without introduc-
tion of any genetic modiﬁcation. The process occurs within days
as revealed by lentivirus-mediated b-cell lineage tracing. Con-
verted cells are indistinguishable from native a-cells based on
ultrastructural morphology and maintain their a-cell phenotype
after transplantation in vivo. Transition of b-cells into a-cells
occurs after b-cell degranulation and is characterized by the pres-
ence of b-cell–speciﬁc transcription factors Pdx1 and Nkx6.1 in
glucagon
+ cells. Finally, we show that lentivirus-mediated knock-
down of Arx, a determinant of the a-cell lineage, inhibits the
conversion. Our ﬁndings reveal an unknown plasticity of human
adult endocrine cells that can be modulated. This endocrine cell
plasticity could have implications for islet development, (patho)
physiology, and regeneration. Diabetes 62:2471–2480, 2013
T
he composition and architecture of human islets
of Langerhans has been studied for years within
their native environment, the pancreas. More
recently, the development of islet transplantation
as a novel therapeutic option for patients with severe
b-cell loss has promoted the study of isolated human islets
and single endocrine cells (1). The majority of pancreatic
islets consist of two main cell types that together play
a key role in glucose homeostasis: insulin-producing
b-cells (50–70%) and glucagon-producing a-cells (20–30%)
(1,2). Human islets display a unique architecture that
favors contacts between b-cells and a-cells, while both cell
types remain in close relation to the vasculature (3).
a- and b-Cells originate from a common neurogenin 3
(Ngn3)-expressing endocrine progenitor (4). The balance
between transcription factors Aristaless-related homeobox
(Arx) and paired box4 (Pax4) likely determines the early
fate restriction of a-a n db-cells, respectively (5). Further
maturation of b-cells is enabled by the expression of
Nkx6.1 (6), while b-cell function is maintained in the adult
pancreas by key transcription factors like Pdx1, MafA, and
FoxO1 (7).
Strategies to convert postnatal cells derived from the
endodermal lineage into endocrine cells have gained much
attention in recent years. Forced expression of key tran-
scription factors in murine liver (8,9) or pancreatic cells
(10–12) induces conversion into cells with a b-cell phe-
notype. Furthermore, in mice, near-total loss of b-cell mass
causes a small proportion of remaining a-cells to re-
generate b-cell mass (13).
It is generally thought that human endocrine cells do not
switch their hormone production once fully differentiated.
Without using genetic modiﬁcation of human islet cells, we
n o ws h o wt h a tb-cells spontaneously convert into glucagon-
producing a-cells during islet cell reaggregation.
RESEARCH DESIGN AND METHODS
Human islet isolation and cell culture. Human islet isolations were per-
formed in the Good Manufacturing Practice facility of our institute according
to the method described by Ricordi et al. (14). Islets were dispersed into
single cells by adding 0.025% trypsin solution containing 10 mg/mL DNase
(Pulmozyme, Genentech) at 37°C while pipetting up and down for 6–7 min.
The islet cell suspension was plated onto 3% agarose microwell chips containing
2,865 microwells/chip with a diameter of 200 mm/microwell (15). Suspension of
3 3 10
6 cells per chip resulted in spontaneous reaggregation of ~1,000 islet cells/
microwell. Islet cell aggregates and intact human islets (control) were cultured
in CMRL 1066 medium (5.5 mmol/L glucose) containing 10% FCS, 20 mg/mL
ciproﬂoxacin, 50 mg/mL gentamycin, 2 mmol/L L-glutamin, 0.25 mg/mL fungi-
zone, 10 mmol/L HEPES, and 1.2 mg/mL nicotinamide.
Lentivirus vectors. pTrip-RIP405Cre-ERT2-DU3 (RIP-CreERT2) and pTrip–
loxP-NEO-STOP-loxP-eGFP-DU3 (CMVstopGFP) were kindly provided by
P. Ravassard (16). pTrip vectors were produced as third-generation lentivirus
vectors by adding a Tat-expressing vector to the regular helper plasmids. The
short hairpin (sh)RNA construct against Arx (shArx) was obtained from the
MISSION library (clone no. 6591, nontarget control no. SHC-002; Sigma-
Aldrich) and produced as previously described (17). For lineage tracing,
transduction was performed as previously described (16). Brieﬂy, dispersed
islet cells were transduced overnight with a 1:1 mixture of the two lentiviruses
at a multiplicity of infection of 2 in regular CMRL medium containing 8 mg/mL
polybrene. In experiments using the shArx construct, a second round of
transduction was subsequently performed for 8 h. 4-hydroxy-tamoxifen
(Sigma-Aldrich, St. Louis, MO) was added to a ﬁnal concentration of 1 mmol/L
in the evening. After overnight incubation, the medium was refreshed and cells
were seeded on the microwell. The start of reaggregation represents day 0 in
our experiments.
RNA isolation and quantitative PCR. Total RNA was extracted using
RNeasy kit (Qiagen) according to the manufacturer’s protocol. Total RNA (1 mg)
was reverse transcribed using M-MLV reverse transcriptase (Invitrogen).
Quantitative PCR was performed on a Light Cycler 480-II Real-time PCR
system (Roche). Fold induction was calculated using DCT method with hu-
man b-actin as housekeeping gene. Primers used are listed in Supplementary
Table 1.
Immunoﬂuorescence staining. Formalin-ﬁxed islet cell aggregates were
washed in PBS and spun down at high speed in ﬂuid agar. Agar-containing cell
pellets were embedded in parafﬁn.Blocks were cut into 4-mm sections. Primary
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ORIGINAL ARTICLEantibodies against insulin (1:200; Linco), C-peptide (1:1,000; Millipore), glu-
cagon (1:200; Vector and Invitrogen), Pdx1 (1:5; R&D Systems), Nkx6.1 (clone
F55A12, 1:1,000; Developmental Studies Hybridoma Bank), Ki67 (1:200; BD
Pharmingen), and green ﬂuoroscent protein (GFP) (1:500; Roche and Molec-
ular Probes) were used. DAPI (Vector) was used as nuclear counterstaining.
Secondary antibodies were TRITC–anti–guinea pig (1:400; Jackson) and Alexa
Fluor 488-, 568-, and 647 anti-mouse or anti-rabbit when appropriate (1:1,000).
Apoptosis was assessed by TUNEL assay (Roche). Sections were examined
using confocal microscopy. Staining was quantiﬁed as percentage of positive
cells per total cell number, counting at least 750 cells per donor for each
condition.
Glucose-stimulated insulin secretion. Four groups of 30 aggregates per
condition were incubated in a modiﬁed Krebs-Ringer bicarbonate buffer. Islets
were successively incubated for 1 h in Krebs-Ringer bicarbonate buffer with 2
FIG. 1. Human islet cell aggregate formation results in an increase in glucagon
+ cells. A: Culture of dispersed islet cells in microwells (diameter
200 mm) results in homogenously sized islet cell aggregates that remain intact after ﬂushing them out of the microwells. Scale bars: 200 mm.
B: Human islet cell aggregate formation results in a distinct architecture after reaggregation: b-cells (insulin, red) are located at the rim and
a-cells in the center (glucagon, green). Scale bars: 100 mm. C: Over time, an increased proportion of glucagon
+ cells was present in islet cell
aggregates. Data are presented as means 6 SEM. n =4 –9 donors. *P < 0.05, **P < 0.005 vs. intact islets glucagon; #P < 0.05 vs. intact islets insulin.
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by ELISA (Mercodia, Uppsala, Sweden).
Electron microscopy. Islet cell aggregates were ﬁxed in 1.5% glutaraldehyde
and postﬁxed in 1% osmium tetroxide for conventional transmission electron
microscopy. 100-nm-thin sections were poststained with uranyl acetate and
lead citrate for ultrastructural analysis. For immunogold labeling, cells were
ﬁxed in 0.2% glutaraldehyde and 2% paraformaldehyde. Sections were stained
using rabbit anti-GFP (1:100), rabbit anti-glucagon (1:200), and mouse anti–
C-peptide (1:1,000; Millipore), and binding was identiﬁed using protein A gold
(10- or 15-nm labels). Images were made on an FEI Tecnai 12 BioTwin
transmission electron microscope. Automated stitching of electron micro-
graphs was performed as previously described (18). Stitched images were
quantiﬁed using ImageScope software.
Animal transplantation. All animal experiments were approved by the Leiden
University Medical Center committee for animal ethics. Human islet cell
aggregates were transplanted under the kidney capsule of 7- to 12-week-old
male NOD/SCID mice. After 2 weeks, grafts were removed for histology.
Statistical analysis. Data are expressed as means 6 SEM unless stated
otherwise. Statistical signiﬁcance of differences between groups were de-
termined by an unpaired Student t test or by one-way ANOVA followed by
Bonferroni multiple comparisons test, as appropriate. P , 0.05 was consid-
ered statistically signiﬁcant.
RESULTS
Human islet cell aggregate formation results in an
increase in glucagon
+ cells. Human islets were isolated
from pancreas of organ donors (average age 52 years
[range 19–71] [Supplementary Table 2]) to $70% purity as
determined by dithizone staining (Supplementary Fig. 1A).
The starting population of intact islets was further char-
acterized by immunostaining and showed 30.1 6 3.9%
b-cells, 8.1 6 1.9% glucagon-immunoreactive cells, and
20.6 6 5.2% duct cells (Fig. 1 and Supplementary Fig. 1B).
For functional and histological studies on islet cell aggre-
gates with a predeﬁned size, human islets were dispersed
into single cells followed by reaggregation during culture
in agarose-based microwells. One thousand islet cells were
seeded per microwell resulting in the formation of human
islet cell aggregates with a diameter of 131 6 10 mm
(Fig. 1A). Compared with intact islets, human islet cell
aggregates showed an unusual architecture after 7 days:
insulin
+ cells were typically found at the rim, and gluca-
gon
+ cells were located in the center of the aggregates
(Fig. 1B). Furthermore, within 4 days of reaggregation the
percentage of insulin-immunoreactive cells was signiﬁ-
cantly decreased (Fig. 1C). This decrease was accompa-
nied by a decrease in gene expression of insulin, pdx1 and
mafa. In line, immunolabeling for Pdx1 was decreased
after reaggregation (Supplementary Fig. 1C and D). In
contrast, the percentage of glucagon-immunoreactive cells
was signiﬁcantly increased during the 14-day reaggregation
period, accompanied by a tendency in increased gene ex-
pression (Fig. 1C and Supplementary Fig. 1C). We ﬁrst
assessed whether these changes were due to b-cell loss or
a-cell proliferation. TUNEL assay showed overall ,2% ap-
optotic cells, while ,1% cell proliferation (Ki67) was ob-
served, of which only 4 of 115 Ki67
+ cells were also
glucagon immunoreactive. No signiﬁcant differences in la-
beling between isolated islets and at 4, 7, or 14 days of re-
aggregation were detected that could explain the change in
cell composition (Fig. 2).
Increased number of glucagon
+ cells results from the
conversion of b-cells. In order to explain the decrease in
insulin
+ cells and increase in glucagon
+ cells, we hypoth-
esized that a subpopulation of b-cells converts into a-cells.
For tracing b-cell fate directly, dispersed islet cells were
transduced with RIP-Cre-ERT2 and CMV-loxP-NEO-STOP-
loxP-eGFP lentiviral vectors as shown previously (16,19).
Tamoxifen administration results in sustained GFP ex-
pression in cells that express insulin at time of the trans-
duction (Fig. 3A and B and Supplementary Fig. 2A, C, and
E). We veriﬁed the efﬁciency and speciﬁcity of the lineage-
tracing system by immunostaining (Supplementary Fig. 2D
and E). Importantly, ,1% of GFP
+ cells expressed gluca-
gon 1 day after tamoxifen administration (Supplementary
Fig. 2E). After 7 days of islet aggregate formation in the
FIG. 2. Change in endocrine hormone distribution is not due to apoptosis or proliferation. A and B: Representative picture of TUNEL assay
combined with insulin staining (A) and Ki67 staining with glucagon (B). C: Quantiﬁcation of apoptotic and proliferating cells deﬁned by the
number of positive nuclei in counted cells. Data are presented as means 6 SEM. n =3 –6 donors.
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+ cells were positive for insulin or
C-peptide (Fig. 3C). Intriguingly, up to 15% of GFP
+ cells
coexpressed glucagon after 14 days (Fig. 3D and E). This
was conﬁrmed by whole mount confocal imaging to de-
tect epiﬂuorescent GFP in cells immunolabeled for glu-
cagon, excluding GFP antibody artifacts (Supplementary
Fig. 3A). The presence of GFP
+/glucagon
+ cells was fur-
ther conﬁrmed by the detection of glucagon
+ cells after
ﬂuorescence-activated cell sorting of the GFP
+ fraction
after redispersion of the islet cell aggregates (Supple-
mentary Fig. 3B). GFP
+/glucagon
+ cells remained present
even after transplantation of the islet cell aggregates in
vivo under the kidney capsule of NOD/SCID mice (Fig. 3F).
The presence of GFP
+ cells did not signiﬁcantly change
over time during the lineage-tracing experiments in vitro
and in vivo (data not shown). Of note, both the typical
architecture and the cell conversion were observed after
reaggregation in six-well ultra-low attachment plates,
excluding the possibility that the microwell culture system
is involved directly (data not shown).
Converted cells have an a-cell phenotype based on
ultrastructural morphology. For determination of
whether the converted b-cells, deﬁned as GFP
+/glucagon
+
cells, have an a-cell ultrastructure, electron microscopy
was performed. Secretory granules containing insulin can
be distinguished from secretory granules containing other
islet hormones based on their ultrastructure (20). Immu-
nogold labeling for GFP conﬁrmed colocalization with
cells containing insulin granules but also demonstrated
colocalization with cells containing more homogeneous,
darker, dense granules typical of a-cells (Fig. 4A and B).
Double immunogold labeling for GFP and glucagon
showed that 51% of GFP
+ cells contained insulin granules,
while 29% contained typical, immunogold-labeled glucagon
granules after 14 days (Fig. 4C and Supplementary Fig. 4A
and B). Granule morphology and localization were identical
FIG. 3. Increased number of glucagon
+ cells results from the conversion of b-cells. A: Schematic representation of conditional b-cell–speciﬁc
lineage tracing using two lentiviral vectors. B: Live cell imaging of transduced human islet cell aggregates shows an equal distribution of epi-
ﬂuorescent GFP throughout the microwell chip. C: After 7 days of reaggregation, GFP
+ cells are observed that do not express insulin (arrows).
D and E: Glucagon
+/GFP
+ cells (arrows) are present in human islet cell aggregates (D) with increasing numbers over time (E). Data are presented
as means 6 SEM. n =3 –6 donors. *P < 0.05. F: Glucagon
+/GFP
+ cell (arrows) in a graft after transplantation under the kidney capsule of NOD/SCID
mice. Scale bars = 50 mm, except for B: 200 mm.
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GFP
+ cells containing the homogeneous, darker, dense
granules typical of a-cells were positive for glucagon
immunogold, thereby conﬁrming the preferential conversion
of b-cells into a-cells. Furthermore, of 254 counted cells, 18%
of GFP
+ cells were determined as degranulated (,10 gran-
ules) and 1 cell contained large amylase granules. Thus, in
combination with the lineage tracing, our data demonstrate
that mature human b-cells can convert into glucagon-
producing a-cells within days of culture after dispersion
and reaggregation.
b-Cell degranulation occurs during human islet cell
aggregate formation. To get an insight into the mecha-
nism of b-t oa-cell conversion, we studied in more detail
the early events after dispersion and reaggregation. First of
all, using immunostaining no coexpression of glucagon
with insulin (Fig. 1B) or C-peptide (data not shown) was
detected 4, 7, or 14 days after reaggregation. To ensure the
absence of bihormonal cells at the level of single granules,
we conﬁrmed these ﬁndings by electron microscopy
performing double labelings for glucagon and C-peptide.
(Supplementary Fig. 5). However, immunostaining within
the ﬁrst 5 days after reaggregation showed up to 50% of
cells negative for insulin but positive for the b-cell–speciﬁc
transcription factors Pdx1 or Nkx6.1, indicating b-cell de-
granulation (Fig. 5A and B and data not shown). This was
conﬁrmed by ultrastructural analysis showing that 77% of
b-cells contained ,70 granules after 4 days’ reaggregation
compared with only 32% of b-cells in intact islets (Fig. 5C
and D). Altogether, these data show that dispersion fol-
lowed by reaggregation results in degranulated b-cells that
may still contain speciﬁc transcription factors.
b-Cell–to–a-cell transition is demonstrated by gluca-
gon
+ cells that express b-cell transcription factors.
Next we hypothesized that, during the transition phase,
cells that lost insulin might coexpress b-cell transcription
factors and glucagon. Using b-cell lineage tracing, we
show the presence of cells expressing Nkx6.1 or Pdx1
together with glucagon and GFP (Fig. 6A). Interestingly,
the percentage of cells coexpressing Pdx1 and glucagon
FIG. 4. Converted cells are regular a-cells based on ultrastructural morphology. A and B: Immunogold labeling for GFP (15-nm gold particles) is
present as black dots in both cells with granules with a typical crystalline structure containing insulin (A) and cells with more homogenous dark
and dense noninsulin granules (B). C and D: Double immunogold labeling for GFP (10-nm gold particles) and glucagon (15-nm gold particles)
shows the presence of a-cell granules in both GFP
+ (converted) and GFP
2 cells (C). Immunogold labeling for GFP is absent within granules (D).
The borders between the cells are marked manually by a broken line (Nu = nucleus). All scale bars = 500 nm.
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+
cells at 7 days of reaggregation (Fig. 6B). In addition, using
immunoelectron microscopy we observed the presence
of GFP
+ cells that contain only very few (,10) glucagon-
labeled granules, suggesting recent transition after de-
granulation (Fig. 6C).
Arx knockdown inhibits the conversion of b-cells into
a-cells. Arx gene expression was increased in human islet
cell aggregates (Fig. 7A). To investigate the role of Arx in
the conversion process, we knocked down Arx gene ex-
pression using a lentivirus-mediated shRNA against arx
(shArx). Knockdown was accompanied by a signiﬁcant
decrease in glucagon mRNA and a trend toward induction
of pax4 and insulin gene expression (Fig. 7B). b-Cell–
speciﬁc lineage tracing revealed that Arx knockdown in-
creased the number of GFP
+/insulin
+ cells almost twofold,
while the number of GFP
+/glucagon
+ cells decreased by
40% (Fig. 7C–E). Finally, shArx-treated cells showed
higher glucose-induced insulin secretion than cells treated
and transduced with a nontarget (control) shRNA (average
stimulation index 5.5 6 2.5 for shCtrl [control] vs. 8.3 6
0.6 for shArx) in two independent experiments (Fig. 7F).
These data demonstrate that the conversion of human
b-cells into glucagon-producing a-cells can be modulated
by changing the expression of a key transcription factor.
DISCUSSION
Mature human b-cells are typically considered as termi-
nally differentiated cells that do not switch their hormone
production once fully differentiated. Our results show that
human b-cells can convert rapidly and preferentially into
glucagon-producing a-cells without forced expression of
exogenous transcription factors. Of importance, the con-
version occurred in islets from pancreas of organ donors
from different backgrounds, independent of donor factors
such as age or sex.
FIG. 5. Reaggregation is accompanied by b-cell degranulation. A: Immunostaining for Pdx1 (green) and C-peptide (red) in intact islets and 5 days
after reaggregation. Scale bars = 100 mm. B: Quantiﬁcation of the number of Pdx1
+/C-peptide
2 cells. Data are presented as means 6 SEM. n =3
donors. **P < 0.005. C: Electron microscopy photographs showing insulin granules in intact islet b-cells and 4 days after reaggregation. Scale
bars = 1 mm. D: Distribution of the amount of insulin granules per b-cell in intact islets and 4 days after reaggregation (for representation of the
distribution, granule number in intact islets was divided in tertiles; >50 cells were counted per condition).
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differentiation have been reported. This usually requires
the forced expression of transcription factors or miRNAs
to convert human ﬁbroblasts into neurons, hematopoietic
progenitors, or brown fat cells (21) or human liver cells
into b-cells (22). In our three-dimensional culture system,
the dispersion into single cells followed by reaggregation
into islet cell aggregates is likely to be a critical step for
cell conversion. Previous lineage-tracing studies in human
b-cells after dispersion and two-dimensional culture show
rapid epithelial-to-mesenchymal transition and no genera-
tion of a-cells (16,23). In this context, the speciﬁc archi-
tecture of islet cell aggregates is of interest, as b-cells were
mainly located at the periphery and a-cells in the center
of the aggregates. Hence, cell-cell and cell-matrix inter-
actions that are disrupted and reestablished, or the changed
cell composition and paracrine signaling between islet cells
within the aggregates, could be mechanistically linked to
our observations.
The mechanisms by which islet cell conversion occur
include direct conversion from one endocrine cell type
into another or dedifferentiation into a progenitor stage
followed by the acquisition of a new endocrine cell phe-
notype (24). Although the short time period for the con-
version to occur and the presence of cells coexpressing
glucagon and b-cell–speciﬁc transcription factors indicate
a direct b-t oa-cell conversion, we cannot rule out a very
transient dedifferentiation stage. Along this line, Talchai
et al. (25) reported that murine FoxO1-deﬁcient b-cells
ﬁrst dedifferentiate to a progenitor-like stage expressing
Ngn3, Oct4, Nanog, and L-myc and subsequently convert
into a-cells. In contrast, Thorel et al. (13) showed direct
conversion of a-cells into b-cells after near-total b-cell ab-
lation through the presence of bihormonal cells (glucagon
+/
insulin
+), thereby indicating that distinct mechanisms of
islet cell conversion may underlie these studies.
Maintenance of b-cell functional maturity is ascribed to
two possible mechanisms: either passive or active control
(7). Whereas the ﬁrst option consists of transient activa-
tion of transcription factors that lock the cell in a mature
state, the second theory relies on continuously active
regulators that maintain a differentiated state. We now
show that adult human b-cells display potential plasticity,
favoring the second hypothesis. Accordingly, this plasticity
is accompanied by the downregulation of key b-cell tran-
scription factors such as Pdx1, Nkx6.1, and MafA. More-
over, knockdown of the a-cell factor Arx could block the
conversion, indicating that b-cell plasticity depends on the
presence or absence of active modulators. This is in line
with recent data from transgenic mouse models (DNMT
2/2
and Nkx2.2
TNmut/TNmut) that indicate that b-cell identity is
maintained by active repression of Arx gene transcription
(26,27). We extend these observations by showing that Arx
is pivotal in the maintenance of a b-cell phenotype in hu-
man cells as well, since the downregulation of Arx efﬁ-
ciently blocks the conversion of human adult b-cells.
The (patho)physiological relevance of our ﬁndings in
humans is unclear. An increased a-cell mass has been
FIG. 6. b-t oa-cell transition is marked by the presence of glucagon
+ cells containing b-cell transcription factors. A: Immunostaining for GFP
(green), Pdx1 (red), and glucagon (white) (arrows in enlargement show triple-positive cell). Scale bar = 100 mm. B: Quantiﬁcation of Pdx1
+/
glucagon
+ cells shows an increase during reaggregation (n = 3 donors, *P < 0.05). C: Double immunogold labeling for GFP (10-nm gold particles)
and glucagon (15-nm gold particles) after reaggregation (arrows show single glucagon granules). Scale bar = 1 mm.
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diabetes.diabetesjournals.org DIABETES, VOL. 62, JULY 2013 2477FIG. 7. Arx knockdown inhibits the conversion of b-cells into a-cells. A: Arx gene expression in human islet cell aggregates compared with control
intact islets (n =3 –6 donors). B: shRNA directed against Arx (shArx) results in knockdown of Arx mRNA that is accompanied by changes in
glucagon, Pax4, and insulin mRNA levels (n = 4 donors). C: Combining b-cell lineage tracing and shRNA treatment shows a large proportion of
GFP
+/insulin
2 cells in shCtrl-treated islet cell aggregates but an increase in GFP
+/insulin
+ cells in shArx-treated islet cell aggregates. D and E:T h e
number of remaining b-cells is increased in shArx-treated aggregates compared with shCtrl (D), while the number of converted cells is decreased
as represented by GFP
+/glucagon
+ cells (E)( n = 4 donors). F: Representative graph of a glucose-stimulated insulin secretion assay that shows
increased insulin secretion after treatment with shArx (mean 6 SD of quadruplicates). All experiments were performed after 7–14 days’ re-
aggregation. Scale bars = 50 mm. *P < 0.05, **P < 0.005, ***P < 0.0001.
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tion that is also characterized by hyperglucagonemia,
but this hypothesis has been challenged by a recent
study in 50 patients (29). Interestingly, recent work from
Talchai et al. (25) associates metabolic stress and type 2
diabetes in mice with b-cell dedifferentiation and con-
version into a-cells (25). This is in line with studies on
rats that suffer from chronic hyperglycemia after partial
pancreatectomy, showing progressive loss of b-cell dif-
ferentiation and a strong reduction in expression of
b-cell transcription factors (30). In our human model,
the substantial b-cell stress that is induced during the
dispersion and reaggregation is likely to be an important
factor as well. This could explain why near-total a-cell
ablation in mice does not induce conversion of b-cells
into a-cells. Since glucose homeostasis was hardly af-
fected, it may be that b-cell stress in this experiment was
limited (31).
Our data have potential relevance for regenerative
strategies in diabetes. We show that without genetic
modiﬁcation, conversion of one human islet cell type into
another can be achieved. Identiﬁcation of the signals that
are relevant for maintenance and change of islet cell
identity could be useful in the quest for generation of
b-cells from alternative cell sources.
In conclusion, we provide a proof of principle that
postnatal human b-cells can undergo a change in en-
docrine cell identity. It remains to be investigated
whether other human endocrine cell types display the
same plasticity and whether this phenomenon plays
a role in vivo. Understanding the mechanisms by which
adult b-cells maintain or change their identity can have
important implications for understanding islet devel-
opment, (patho)physiology, and regenerative strategies
in diabetes.
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